Product Information
CELLCEPT 200 MG/ML ORAL SUSP is a brand product labeled by Genentech, Inc., priced at $8.3144 per ML under NDC 00004026129. Its NADAC has been published 441 times since Nov 28, 2013.
FDA first approved this application on Oct 1, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Mycophenolate Mofetil market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200 mg/mL
Manufacturer
Genentech, Inc.NDC
00004026129
Classification
Brand
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MYCOPHENOLATE MOFETILApproval Type
New Drug (NDA)
FDA Application
NDA050759FDA Approved
10/1/1998
TE Code
AB
On Market Since
10/1/1998
Pharmacological Classes
Price Statistics
The NADAC for CELLCEPT 200 MG/ML ORAL SUSP has been published 441 times since Nov 28, 2013, and over the history we have for it it has risen 39.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.3144 per ML |
|---|---|
| All-time high | $8.4086 (Feb 13, 2019) |
| All-time low | $5.9684 (Nov 28, 2013) |
| 52-week high | $8.3454 |
| 52-week low | $8.3144 |
| Median price | $8.3081 |
| Average price | $7.7458 |
| Largest weekly change | +9.5% (Nov 18, 2015) |
| Weeks tracked | 441 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 88% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Genentech, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mycophenolate Mofetil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimetabolite Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CELLCEPT 200 MG/ML ORAL SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CELLCEPT 200 MG/ML ORAL SUSP, manufactured by Genentech, Inc., is $8.3144 per ML (NDC 00004026129), effective Sep 30, 2026.
How has the price of CELLCEPT 200 MG/ML ORAL SUSP changed over time?
Over the history we have for it, the NADAC for CELLCEPT 200 MG/ML ORAL SUSP has risen 39.3%. It has been tracked across 441 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CELLCEPT 200 MG/ML ORAL SUSP?
Since Nov 28, 2013, the NADAC for CELLCEPT 200 MG/ML ORAL SUSP has ranged from a low of $5.9684 (Nov 28, 2013) to a high of $8.4086 (Feb 13, 2019), with a median of $8.3081 per ML.
Are there cheaper alternatives to CELLCEPT 200 MG/ML ORAL SUSP?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MYCOPHENOLATE 200 MG/ML SUSP, is $0.9816 per ML — about 88% below CELLCEPT 200 MG/ML ORAL SUSP.
Who manufactures CELLCEPT 200 MG/ML ORAL SUSP?
CELLCEPT 200 MG/ML ORAL SUSP (NDC 00004026129) is labeled by Genentech, Inc., and CMS classifies it as a brand product.